Argent BioPharma (ASX:RGT) is working with European pharmaceutical manufacturer ECCPharm, according to a Wednesday filing with the Australian bourse.
Under the agreement, ECCPharm will handle manufacturing and batch release responsibilities for Argent's cannabinoid therapies, CannEpil and CogniCann, ensuring access to these therapies through early patient programs in European countries, including Ireland, the UK, and Germany, the filing said.
As part of the deal, ECCPharm will oversee the transfer of manufacturing operations from Argent BioPharma's current facilities to ECCPharm's production facility in North Macedonia, the filing added.
Argent will cover all costs associated with the technology transfer and retain ownership of its research and development pipeline, along with all intellectual property rights.
Shares of the company rose past 17% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.